AU2022213335A1 - Advantageous morphic form of at-527 hemi-sulfate salt - Google Patents

Advantageous morphic form of at-527 hemi-sulfate salt Download PDF

Info

Publication number
AU2022213335A1
AU2022213335A1 AU2022213335A AU2022213335A AU2022213335A1 AU 2022213335 A1 AU2022213335 A1 AU 2022213335A1 AU 2022213335 A AU2022213335 A AU 2022213335A AU 2022213335 A AU2022213335 A AU 2022213335A AU 2022213335 A1 AU2022213335 A1 AU 2022213335A1
Authority
AU
Australia
Prior art keywords
compound
form iii
pharmaceutical composition
virus
solid dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022213335A
Other languages
English (en)
Inventor
Adel Moussa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atea Pharmaceuticals Inc
Original Assignee
Atea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atea Pharmaceuticals Inc filed Critical Atea Pharmaceuticals Inc
Publication of AU2022213335A1 publication Critical patent/AU2022213335A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Thermal Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AU2022213335A 2021-01-26 2022-01-26 Advantageous morphic form of at-527 hemi-sulfate salt Pending AU2022213335A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163141789P 2021-01-26 2021-01-26
US63/141,789 2021-01-26
PCT/US2022/013953 WO2022164941A1 (en) 2021-01-26 2022-01-26 Advantageous morphic form of at-527 hemi-sulfate salt

Publications (1)

Publication Number Publication Date
AU2022213335A1 true AU2022213335A1 (en) 2023-07-27

Family

ID=82653876

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022213335A Pending AU2022213335A1 (en) 2021-01-26 2022-01-26 Advantageous morphic form of at-527 hemi-sulfate salt

Country Status (12)

Country Link
US (2) US20230365611A1 (https=)
EP (1) EP4284389A4 (https=)
JP (1) JP2024504392A (https=)
KR (1) KR20230135635A (https=)
CN (1) CN116744939A (https=)
AU (1) AU2022213335A1 (https=)
BR (1) BR112023014825A2 (https=)
CA (1) CA3173656A1 (https=)
IL (1) IL304402A (https=)
MX (1) MX2023008746A (https=)
TW (1) TW202245806A (https=)
WO (1) WO2022164941A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
AU2022213335A1 (en) * 2021-01-26 2023-07-27 Atea Pharmaceuticals, Inc. Advantageous morphic form of at-527 hemi-sulfate salt
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial
WO2024211746A1 (en) * 2023-04-06 2024-10-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Treatment of autoimmune diseases and cancer with protease inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US20180214370A1 (en) * 2017-01-31 2018-08-02 L'oreal Topcoat for long-wear lip compositions
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
JP2022510014A (ja) * 2018-12-05 2022-01-25 アテア ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎ウイルスの治療のための高活性な合剤
US10874687B1 (en) * 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
AU2022213335A1 (en) * 2021-01-26 2023-07-27 Atea Pharmaceuticals, Inc. Advantageous morphic form of at-527 hemi-sulfate salt

Also Published As

Publication number Publication date
KR20230135635A (ko) 2023-09-25
JP2024504392A (ja) 2024-01-31
US20230365611A1 (en) 2023-11-16
TW202245806A (zh) 2022-12-01
EP4284389A4 (en) 2025-04-16
EP4284389A1 (en) 2023-12-06
WO2022164941A1 (en) 2022-08-04
MX2023008746A (es) 2023-08-01
CN116744939A (zh) 2023-09-12
US20260035404A1 (en) 2026-02-05
IL304402A (en) 2023-09-01
CA3173656A1 (en) 2022-08-04
BR112023014825A2 (pt) 2023-10-03

Similar Documents

Publication Publication Date Title
US20260035404A1 (en) Advantageous morphic form of at-527 hemi-sulfate salt
US12226429B2 (en) Highly active compounds against COVID-19
EP3061452B1 (en) Icaritin for use in preventing or treating hematocytopenia
TW202033515A (zh) 用於治療c型肝炎病毒之高活性藥物組合
WO2021173713A1 (en) Highly active compounds against covid-19
JP2018529777A (ja) Ｈｃｖの治療に対する併用療法レジメン
KR20240022574A (ko) 유리한 항-hcv 조합 요법
US20180021361A1 (en) Combination drug treatment for hepatitis c infection
HK40099393A (en) Highly active compounds against covid-19
HK40061232B (en) Highly active compounds against covid-19